Hereditary medullary thyroid cancer: Age-appropriate thyroidectomy improves disease-free survival

Annals of Surgical Oncology

Volumn 20, Issue 5, 2013, Pages 1451-1455

  Shepet, Kevin ^a   Alhefdhi, Amal ^a   Lai, Ngan ^a   Mazeh, Haggi ^a   Sippel, Rebecca ^a   Chen, Herbert ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; AGE; ARTICLE; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; PRESCHOOL CHILD; PROSPECTIVE STUDY; RECURRENCE RISK; SEX DIFFERENCE; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

ADOLESCENT; AGE FACTORS; CARCINOMA, MEDULLARY; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES AS TOPIC; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROIDECTOMY; TIME FACTORS;

EID: 84880067672     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2757-9     Document Type: Article

References (16)

1. Chen H, Sippel RS, O'Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775-83.
2. Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist. 2008;13(5):539-47.
3. Greenblatt DY, Chen H. Palliation of advanced thyroid malignancies. Surg Oncol. 2007;16(4):237-47.
4. Chen H, Roberts JR, Ball DW, et al. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg. 1998;227(6):887-95.
5. Moley JF, Lairmore TC, Phay JE. Hereditary endocrinopathies. Curr Prob Surg. 1999;36(9):653-762.
6. Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet. 2000;37(11):817-27.
7. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Mol Genet. 1993;2(7):851-6.
8. Pinchot SN, Sippel RS, Chen H. Multi-targeted approach in the treatment of thyroid cancer. Ther Clin Risk Manag. 2008;4(5):935-47.
9. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575-9.
10. Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005;15(6):531-44.
11. Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Eng J Med. 2005;353(11):1105-13.
12. O'Riordain DS, O'Brien T, Weaver AL, et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery. 1994;116(6):1017-23.
13. Schreinemakers JMJ, Vriens MR, Valk GD, et al. Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study. World J Surg. 2010; 34(4):852-60.
14. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. N Eng J Med. 2003;349(16):1517-25.
15. Wolfe HJ, Melvin KE, Cervi-Skinner SJ, et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Eng J Med. 1973;289(9):437-41.
16. Kloos R, Eng C, Evans D, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565-612. Training Grant